4.0 Article

Increased in-hospital mortality from COVID-19 in patients with schizophrenia

Publisher

MASSON EDITEUR
DOI: 10.1016/j.encep.2020.07.003

Keywords

Schizophrenia; Psychiatry; COVID-19; Observational study

Funding

  1. Assistance Publique-Hopitaux Marseille (AP-HM) - Aix-Marseille University (AMU)
  2. European Health Data & Evidence Network from the European Union

Ask authors/readers for more resources

This study compared the clinical characteristics and outcomes of COVID-19 patients with schizophrenia (SCZ) to non-SCZ patients. The results showed that SCZ patients had a higher mortality rate but similar ICU admission rates compared to non-SCZ patients. Additionally, SCZ patients were more likely to have cancers and respiratory comorbidities.
Background - There is limited information describing the presenting characteristics and outcomes of patients with schizophrenia (SCZ) requiring hospitalization for coronavirus disease 2019 (COVID-19). Aims- We aimed to compare the clinical characteristics and outcomes of COVID-19 SCZ patients with those of non-SCZ patients. Method - This was a case-control study of COVID-19 patients admitted to 4 APHM/AMU acute care hospitals in Marseille, southern France. COVID-19 infection was confirmed by a positive result on polymerase chain reaction testing of a nasopharyngeal sample and/or on chest computed scan among patients requiring hospital admission. The primary outcome was in-hospital mortality. The secondary outcome was intensive care unit (ICU) admission. Results - A total of 1092 patients were included. The overall in-hospital mortality rate was 9.0%. The SCZ patients had an increased mortality compared to the non-SCZ patients (26.7% vs. 8.7%, P = 0.039), which was confirmed by the multivariable analysis after adjustment for age, sex, smoking status, obesity and comorbidity (adjusted odds ratio 4.36 [95% CI: 1.0917.44]; P = 0.038). In contrast, the SCZ patients were not more frequently admitted to the ICU than the non-SCZ patients. Importantly, the SCZ patients were mostly institutionalized (63.6%, 100% of those who died), and they were more likely to have cancers and respiratory comorbidities. Conclusions - This study suggests that SCZ is not overrepresented among COVID-19 hospitalized patients, but SCZ is associated with excess COVID-19 mortality, confirming the existence of health disparities described in other somatic diseases. (C) 2020 L'Encephale, Paris.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available